DBT and clear cell renal carcinoma: In clear cell renal cell carcinoma (ccRCC), METTL3-m6A modification reduces dihydrolipoamide branched chain transacylase E2 (DBT) expression and promotes tumor progression and corrects the lipid metabolism disorder [133].